Humacyte, Inc. (HUMA), a commercial-stage biotechnology platform, announced positive top-line interim results from the Phase 3 study dubbed V012 by meeting the trial's primary endpoint of the acellular tissue-engineered vessel (ATEV) in female patients undergoing dialysis access.